In the Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes (PHARMCLO) trial (13) conducted in Italy, selecting P2Y12 receptor inhibitors by considering CYP2C19 genetic testing results was demonstrated to reduce ischemic events in patients undergoing PCI, and there were no differences between groups for major bleeding events. This evidence concerns the gene CYP2C19 and acute coronary syndrome.